Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Vamorolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Santhera's Vamorolone Gets Orphan and Priority Review Tags
    Santhera's Vamorolone Gets Orphan and Priority Review Tags

    02 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/02/3304834/0/en/santhera-announces-orphan-drug-and-priority-review-designations-for-agamree-vamorolone-in-south-korea.html

    GLOBENEWSWIRE
    02 Jun 2026
    Share Share
    Nxera's Vamorolone Gains Key DMD Designations in Korea
    Nxera's Vamorolone Gains Key DMD Designations in Korea

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304800/0/en/nxera-s-vamorolone-granted-key-regulatory-designations-supporting-faster-access-for-duchenne-muscular-dystrophy-patients-in-south-korea.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Santhera Reveals AIFA Board Approval For Agamree Reimbursement
    Santhera Reveals AIFA Board Approval For Agamree Reimbursement

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282209/0/en/santhera-announces-positive-aifa-board-decision-on-reimbursement-of-agamree-vamorolone-in-italy.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Santhera Receives Positive CHMP Opinion to Expand Agamree
    Santhera Receives Positive CHMP Opinion to Expand Agamree

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281273/0/en/santhera-receives-positive-chmp-opinion-to-expand-agamree-vamorolone-use-in-pediatric-dmd-patients-aged-two-and-older-in-the-eu.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    AGAMREE Shows Long-Term Safety, Efficacy in Duchenne Disease
    AGAMREE Shows Long-Term Safety, Efficacy in Duchenne Disease

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251502/0/en/AGAMREE-vamorolone-Data-Presented-at-MDA-2026-Confirm-Comparable-Long-Term-Effectiveness-for-up-to-8-Years-of-Treatment-with-Clinically-Meaningful-Safety-Advantages-in-Duchenne-Mus.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Catalyst Pharma Presents Duchenne Muscular Dystrophy Data
    Catalyst Pharma Presents Duchenne Muscular Dystrophy Data

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3251009/13009/en/Catalyst-Pharmaceuticals-to-Showcase-Real-World-Findings-in-Duchenne-Muscular-Dystrophy-and-Host-Vamorolone-Focused-Symposium-at-the-2026-MDA-Clinical-Scientific-Conference.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.